The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Magnus Energy en Ciratum bundelen krachten en nemen het voortouw in de energietransitie
Adviesbureaus Magnus Energy en Ciratum bundelen hun krachten om hun dienstverlening te versterken en te verbreden. Om zo innovatieve, hoogwaardige en holistische oplossingen te bieden aan Nederlandse klanten in de energiesector.
Guiding the energy transition: Magnus Energy and Ciratum unite to lead the way
Magnus Energy and Ciratum have joined forces to elevate their service offerings, delivering innovative, high-quality, and holistic solutions to Dutch customers in the energy sector.
Uman raises EUR 1.9m from Holland Capital to disrupt sales enablement market
Uman, the Belgium-based AI-driven software platform for B2B sales teams, raises 1.9 million euros. The funding round is led by Holland Capital, together with existing investors imec and Seeder Fund.
Gentse AI start-up die de perfecte sales pitch genereert, haalt 1,9 miljoen euro op bij Holland Capital
Uman, het Gentse AI-gedreven softwareplatform voor B2B sales teams, haalt 1,9 miljoen euro op. De financieringsronde wordt geleid door Holland Capital, in combinatie met bestaande investeerders imec en Seeder Fund.
Holland Capital kondigt succesvolle exit van Defibrion aan IK Partners aan
Sinds 2019 heeft het management team van Defibrion op succesvolle wijze samengewerkt met Holland Capital. De aandelen van Defibrion worden verkocht aan IK en Defibrion’s management team.
Holland Capital Announces Successful Exit of Defibrion to IK Partners
Since 2019, Defibrion’s management team has successfully collaborated with Holland Capital. The shares of Defibrion are being sold to IK and the company’s management team.
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl



